Promoter shareholding declined by 42.47% YoY, indicating significant insider selling while sector averages remain stable.

Institutional shareholding unchanged, suggesting a lack of confidence or interest in Bacil Pharma compared to sector trends.

Public shareholding increased by 42.14% YoY, reflecting retail optimism that diverges from the smart money's exit strategy.